Golimumab

Rheumatoid Arthritis
Golimumab, in combination with methotrexate (MTX), is indicated to:

• Reduce signs and symptoms
• Inhibit the progression of structural damage
• Improve physical function
• Improve health-related quality of life in adult patients with moderate to severe rheumatoid arthritis when the response to disease-modifying antirheumatic drug (DMARD) therapy, including MTX, has been inadequate.

Active Psoriatic Arthritis in patients aged 2 years and older, as monotherapy or in combination with methotrexate:
Psoriatic arthritis is an inflammatory joint disease commonly accompanied by psoriasis. If you or your child has active psoriatic arthritis, you will receive Golimumab, either alone or in combination with methotrexate, to:

• Reduce the signs and symptoms of your arthritis
• Improve physical function
• Improve enthesitis (pain and swelling around the joints)
• Improve skin and nail psoriasis
• Improve health-related quality of life.

Ankylosing Spondylitis
Ankylosing spondylitis is an inflammatory disease of the spine. If you have active ankylosing spondylitis, you will receive Golimumab to:

• Reduce the signs and symptoms of your disease
• Improve physical function
• Improve health-related quality of life.

Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Polyarticular juvenile idiopathic arthritis is an inflammatory disease that causes joint pain and swelling in children. If your child has polyarticular juvenile idiopathic arthritis, they will first receive other medications. If your child does not respond adequately to these treatments, they will receive Golimumab to treat the disease.

Golimumab, alone or in combination with MTX, is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in children aged 2 years or older who have had an inadequate response to prior MTX therapy.